Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Dancady1 Nov. 14 at 2:42 PM

$INKT good news and good eps today and it is still down

0 · Reply

crystalfang Nov. 8 at 6:03 AM

$INKT reversal?

0 · Reply

DARKP00L Nov. 7 at 2:23 PM

$INKT 09:07 on Nov. 07 2025 MiNK Therapeutics Presents Updated Clinical Results Evaluating Agent-797, Alone And In Combination With Anti-PD-1 Therapy, In Patients With Advanced Solid Tumors Refractory To All Approved Treatments At SITC 2025 #tradeideas

0 · Reply

Stock_Catcher Nov. 7 at 2:01 PM

$INKT MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

0 · Reply

Rony4AM Nov. 6 at 10:25 PM

0 · Reply

Dancady1 Nov. 4 at 5:08 PM

$INKT pos

0 · Reply

Biotechguy21 Nov. 3 at 3:20 PM

$AGEN $INKT $PTIX POS Stocls. Rotten to the core. 😂😂🤡🤡💩💩

0 · Reply

neversurrender2024 Oct. 31 at 5:18 AM

$INKT another cancer conference is just another fund raiser for garo armen....major dilution coming this way folks....

2 · Reply

Dancady1 Oct. 21 at 3:26 PM

$INKT

0 · Reply

Dgun Oct. 21 at 3:24 PM

$INKT here we go!

0 · Reply

MiNK Therapeutics, Inc. (INKT) Q3 2025 Earnings Call Transcript

$MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025$

Nov 7, 2025, 9:00 AM EST - 7 days ago

MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

Sep 29, 2025, 7:30 AM EDT - 6 weeks ago

MiNK Therapeutics Appoints Colonel (Ret.) John B. Holcomb, MD, to Board of Directors

Sep 25, 2025, 7:30 AM EDT - 7 weeks ago

MiNK Therapeutics Dr. Jennifer Buell to Deliver Featured Plenary at 10th Annual CAR-TCR Summit in Boston, MA

Sep 18, 2025, 7:30 AM EDT - 2 months ago

MiNK Therapeutics Appoints Dr. Terese C. Hammond to Accelerate iNKT Pipeline to Pivotal Development

Aug 14, 2025, 4:15 PM EDT - 3 months ago

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 3 months ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 3 months ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 4 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 4 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 5 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 5 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 6 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 8 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 8 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 9 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 9 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 9 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 10 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 11 months ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 1 year ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 1 year ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 1 year ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 2 years ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 2 years ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results

Dancady1 Nov. 14 at 2:42 PM

$INKT good news and good eps today and it is still down

0 · Reply

crystalfang Nov. 8 at 6:03 AM

$INKT reversal?

0 · Reply

DARKP00L Nov. 7 at 2:23 PM

0 · Reply

Stock_Catcher Nov. 7 at 2:01 PM

$INKT MiNK Therapeutics Reports Durable Responses and Immune Reactivation with Allo-iNKT Cell Therapy agenT-797 in PD-1–Refractory Solid Tumors at SITC 2025

0 · Reply

Rony4AM Nov. 6 at 10:25 PM

0 · Reply

Dancady1 Nov. 4 at 5:08 PM

$INKT pos

0 · Reply

Biotechguy21 Nov. 3 at 3:20 PM

$AGEN $INKT $PTIX POS Stocls. Rotten to the core. 😂😂🤡🤡💩💩

0 · Reply

neversurrender2024 Oct. 31 at 5:18 AM

$INKT another cancer conference is just another fund raiser for garo armen....major dilution coming this way folks....

2 · Reply

Dancady1 Oct. 21 at 3:26 PM

$INKT

0 · Reply

Dgun Oct. 21 at 3:24 PM

$INKT here we go!

0 · Reply

Dgun Oct. 19 at 7:37 PM

$INKT https://agenusbio.com/wp-content/uploads/2025/10/ESMO-2025-17Sept2025_C-800-01-Pan-Tumor-Mini-Oral_FINAL.pdf positive data!! I bullish breakout of pennant pattern

1 · Reply

Tigertkbc Oct. 15 at 11:30 PM

$INKT Actually review on July 10th spike on July 11th. That is a long time!!

0 · Reply

Dancady1 Oct. 15 at 7:57 PM

$INKT

0 · Reply

Tigertkbc Oct. 14 at 7:46 PM

$INKT I am thinking SEC just cares about Football!

0 · Reply

GixxerStuntn Oct. 13 at 9:32 PM

$INKT Watching the pennant pattern here, which way will it break is the question?

0 · Reply

Dancady1 Oct. 11 at 12:26 PM

$INKT is it holding the bottom or what during this black swan

0 · Reply

Dancady1 Oct. 6 at 8:28 PM

$INKT

0 · Reply

sidewayzonly Oct. 5 at 7:50 AM

$INKT Technology services growth. Testing resistance level. Volume expansion needed for continuation. Sector momentum building.

0 · Reply

Biotechguy21 Oct. 2 at 12:43 AM

$INKT $AGEN checking on my favorite two pos of stocks and nothing surprising . Both down. 🤡🤡😂😂

0 · Reply

2_logs_higher Sep. 29 at 2:16 PM

$AGEN & $INKT new bod for mink https://investor.minktherapeutics.com/node/8271/pdf

0 · Reply

neversurrender2024 Sep. 26 at 12:04 PM

$INKT whats the odds that garos dumping shares here to keep the lights on over at $AGEN...ITS going lower here as well folks....stay tuned!

0 · Reply

2_logs_higher Sep. 25 at 1:13 PM

$AGEN & $INKT

0 · Reply

Market Cap	61.87M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	18,203
Avg Vol	33,516
Day's Range	N/A - N/A
Shares Out	4.52M
Stochastic %K	64%
Beta	0.33
Analysts	Strong Sell
Price Target	$39.00